---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-000587"
form_type: "8-K"
ticker: null
cik: "0001872812"
company_name: "TC BioPharm (Holdings) plc"
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:14:39.887200+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TC BioPharm regains Nasdaq minimum bid price compliance, avoids delisting

## Summary
- Received Nasdaq confirmation on Jan 2, 2024, that bid price exceeded $1.00 for 10 consecutive days through Dec 29, 2023.
- Had been out of compliance since June 22, 2023, and initial 180-day cure period expired Dec 19, 2023.
- Company not eligible for second 180-day extension, but regained compliance before delisting became effective.
- Press release issued Jan 4, 2024; matter is closed with Nasdaq.
- Resolution removes overhang of potential transfer to OTC or other exchange.

## SEC filing metadata
- accession: 0001493152-24-000587
- form_type: 8-K
- cik: 0001872812
- company_name: TC BioPharm (Holdings) plc
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1872812/000149315224000587/0001493152-24-000587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1872812/000149315224000587/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-000587
- JSON: https://secwatch.observer/filing/0001493152-24-000587.json
- Plain text: https://secwatch.observer/filing/0001493152-24-000587.txt

## Key facts
- Listing & Compliance Notices
  TC BioPharm (Holdings) plc received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 2, 2024, the Company received written confirmation from Nasdaq that it has determined that for the last 10 consecutive business days, from December 15, 2023 to December 29, 2023, the closing bid price of the Company’s securities has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1872812/000149315224000587/0001493152-24-000587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.